Midyear outlook: North American small-cap equities
The Russell 2000 is still sharply discounted, yet catalysts remain scarce for the gauge to rerate higher — though easing trade tensions and lower rates are the most obvious possible sparks that could ignite some rally. Our Fair Value Model hints that the index's multiple still has some room to rise based on rate consensus, but anemic macro forecasts are still driving a disconnect between the regression's implied growth and bottom-up consensus — the former remains concerned about the weight of trade tensions on the US economy, while the latter appears to expect a swift resolution to tensions. Credit markets continue to sound an all clear, though rising distress in energy is worth watching.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Here's Why Inspire Medical Systems (INSP) Retreated in Q2
Baron Funds, an investment management company, released its 'Baron Discovery Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund was up 14.76% (Institutional Shares), outperforming the 11.97% return for the Russell 2000 Growth Index. The fund was up 7.68% year-to-date, well ahead of the Index's -0.48% return. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Discovery Fund highlighted stocks such as Inspire Medical Systems, Inc. (NYSE:INSP). Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. The one-month return of Inspire Medical Systems, Inc. (NYSE:INSP) was 2.12%, and its shares lost 9.58% of their value over the last 52 weeks. On July 30, 2025, Inspire Medical Systems, Inc. (NYSE:INSP) stock closed at $131.21 per share, with a market capitalization of $3.87 billion. Baron Discovery Fund stated the following regarding Inspire Medical Systems, Inc. (NYSE:INSP) in its second quarter 2025 investor letter: "Inspire Medical Systems, Inc. (NYSE:INSP) is a medical device company offering a treatment option called hypoglossal nerve stimulation for patients with moderate-to-severe obstructive sleep apnea. Shares declined during the second quarter. The company is in the early stages of commercializing its fifth-generation device, Inspire 5, which reduces procedure time and simplifies the process for surgeons. Management noted that some patients delayed surgery in anticipation of the new device, leading to a slowdown in procedures during the quarter. Shares were also pressured by concerns about new competitors entering the market and the potential long-term impact of GLP-1 weight loss drugs on business, given the link between obesity and sleep apnea. Despite these headwinds, we believe Inspire remains well positioned to grow at a healthy rate, supported by its market leadership and the substantial size of the addressable patient population. We believe the current valuation presents a compelling entry point given the company's long-term growth potential." A medical professional performing a minimally invasive procedure while using the company's technology. Inspire Medical Systems, Inc. (NYSE:INSP) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held Inspire Medical Systems, Inc. (NYSE:INSP) at the end of the first quarter, which was 32 in the previous quarter. Inspire Medical Systems, Inc. (NYSE:INSP) generated revenue of $201.3 million in the first quarter of 2025, representing a 23% increase compared to the first quarter of 2024. While we acknowledge the potential of Inspire Medical Systems, Inc. (NYSE:INSP) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Inspire Medical Systems, Inc. (NYSE:INSP) and shared the list of best medical technology stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 days ago
- Yahoo
Is the Vanguard Russell 2000 ETF a Buy Now?
Key Points The Vanguard Russell 2000 ETF tracks 2,000 publicly traded smaller companies. Larger companies are benefiting from AI, and the fund is missing out on some of the momentum in the market. The fund can be a good way to diversify your investments, but it's not for everyone right now. 10 stocks we like better than Vanguard Russell 2000 ETF › Funds tracking the Russell 2000 index have been a mainstay for investors for years, giving them the opportunity to own a little piece of 2,000 U.S.-based small-cap companies. At times, the index has outperformed the S&P 500 during periods of rapid economic expansion. One of the best avenues for investing in the index has been through the Vanguard Russell 2000 ETF (NASDAQ: VTWO) because of its large size and low expense ratio of just 0.07%. But is the Vanguard Russell 2000 ETF the right investment for you right now? Here's what you should know. The case for buying the Vanguard Russell 2000 ETF now Russell 2000 exchange-traded funds are appealing to many investors because they give them a chance to easily diversify their portfolio. Because the funds track the Russell 2000, shareholders have exposure to 2,000 small companies, many of them trying to out-innovate and disrupt much larger rivals. Each large-cap company started out as a small upstart, so it's easy to imagine how getting in on the ground floor of some small disruptors could be a good long-term investment strategy. What's more, the Russell 2000 has had periods of growth that far outpaced the S&P 500's gains. The Russell 2000 rose by 150% from 2009 to 2014, while the S&P 500 increased by 130% in that time frame. Those returns came after the Great Recession, as smaller companies were able to eke out more gains following a very difficult economic time. That's one advantage of investing in the Vanguard Russell 2000 ETF: The share prices of small-cap companies tend to bounce back faster after tough economic times than larger ones. That proved true during the COVID recovery as well, then the Russell 2000 rose faster in response to the federal government's stimulus than the S&P 500 did. Why some investors may be better off putting their cash elsewhere One of the drawbacks of investing in the Vanguard Russell 2000 ETF lately has been that it's mostly missing out on the artificial intelligence boom. While some small companies are benefiting from AI, most of the recent gains in the market have come from large companies making big moves in hardware and software, including Nvidia and Microsoft. This is one of the reasons why the S&P 500 is up about 66% over the past three years, while Vanguard's Russell 2000 fund has gained just 23%. Large tech companies are investing hundreds of billions of dollars into AI right now, and it's fueling a boom in data center infrastructure, cloud computing, data analytics, and AI agents that are collectively worth trillions of dollars. That's simply too big of an opportunity to pass up right now for most investors. Although this Vanguard fund has occasionally outperformed the S&P 500, its focus on smaller companies means it will almost always be more volatile than the broader market. At a time when AI is booming and there's a lot of uncertainty surrounding tariffs and the economy, putting your money into the Vanguard Russell 2000 ETF may not be as wise a move as investing in an S&P 500 ETF. I'll end with another caveat. If you believe the economy is headed for a slowdown soon, having some money in Vanguard's Russell 2000 ETF could be smart. Diversifying your investments is almost always a good idea, and if you're overexposed to larger companies or have too much invested in AI stocks, then spreading your portfolio investments around a bit more might help you weather economic bumps down the road. Should you buy stock in Vanguard Russell 2000 ETF right now? Before you buy stock in Vanguard Russell 2000 ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vanguard Russell 2000 ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Microsoft and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Is the Vanguard Russell 2000 ETF a Buy Now? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Markets Finish July with a Slight Selloff, Plus AAPL, AMZN Report
Thursday, July 31, 2025Markets closed out a strong month of July on a particularly weak note. Leading into the month of August, which typically sees lower trading volume and even some pullbacks on the indexes in certain places, market participants sought to ease up on the market rally. The Dow shed -330 points today, -0.74%, the S&P 500 was down -23 points, -0.37%, the Nasdaq only a mere -7 points, -0.03% — although it had gotten up to 21,412 this morning — and the small-cap Russell 2000 dumped -20 points, -0.93%.A still somewhat murky trade outlook (certainly more fragile than many had expected these trade deals to be by this time in the year) join with recent major economic reports showing the economy warming up again (CPI two weeks ago and PCE this morning) may mean that we really aren't moving off our current spot too quickly. Aside from the clear 'all in' AI investments being made by the top tech firms, things aren't necessarily getting demonstrably better from this vista for the markets to continue setting record closing with the S&P 500 having gained more than +2% for July and the Nasdaq closer to +4%, it's not the worst time in the world to book a few profits. And we're not finished with this week's big news: Friday morning, the nonfarm payrolls and unemployment numbers in the Employment Situation report hit the tape. Plus manufacturing PMI data, construction spending, consumer sentiment and auto sales will greet us tomorrow, as well. Big Afternoon for Earnings Results: AAPL, AMZN & More Apple AAPL shares are up nicely in late trading following its fiscal Q3 report, with earnings of $1.57 per share outpacing the $1.42 in the Zacks consensus, and +12% year over year. Revenues of $94.0 billion easily surpassed projections for $88.9 billion in the quarter. Shares are rallying +3% on the no longer see a breakdown in iPhone and other product sales per quarter, but Apple's Services segment brought in a record-high $27.4 billion for Q3. This now accounts for nearly 30% of Apple's revenues. Today's report is a shot in the arm for the world's biggest gadget maker, which had been trading down -17% year to AMZN posted a most impressive Q2 report this afternoon, with earnings of $1.68 per share dominating the $1.33 analysts had expected, on revenues of $167.7 billion which surged past the $162.3 billion estimate. AWS was +18% year over year, and revenue guidance was ratcheted up for the current quarter. Yet shares are trading lower by more than -2% in the after-market, perhaps on lower-than-expected guidance on Operating ROKU swung to a positive on earnings in its Q2 report out after the bell, with earnings of +$0.07 easily beating the -$0.16 in the Zacks consensus. Revenues of $1.11 billion were an improvement over the$1.07 billion analysts were looking for. Its platform segment grew +18% in the quarter, and is now expected to fetch $4.075 billion for the full but not least, Reddit RDDT shares are up +14% in late trading after stomping estimates on both top and bottom lines this afternoon: earnings of +48 cents per share was far better that the +20 cents estimated and the -6 cents reported in the year-ago quarter. Revenues of $499 million rose +78% year over year, and well past the forecast for $427.4 or comments about this article and/or author? Click here>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN) : Free Stock Analysis Report Apple Inc. (AAPL) : Free Stock Analysis Report Roku, Inc. (ROKU) : Free Stock Analysis Report Reddit Inc. (RDDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
